Fusion of a tumour-associated antigen to HIV-1 tat improves protein-based immunotherapy of cancer

Anticancer Research

Volumn 23, Issue 4, 2003, Pages 3523-3531

  Giannouli, Christina ^a   Brulet, Jean Marc ^a   Gesché, Fabienne ^a   Rappaport, Jay ^a   Burny, Arsené ^a   Leo, Oberdan ^b   Hallez, Sophie ^a,c  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b TEMPLE UNIVERSITY   (United States)

^c Chimie Biologique   (Belgium)

Author keywords

Cancer immunotherapy; HIV 1 Tat; HPV16 E7

Indexed keywords

CANCER VACCINE; GAMMA INTERFERON; HYBRID PROTEIN; QUIL A; TRANSACTIVATOR PROTEIN; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CARBOXY TERMINAL SEQUENCE; CELL MEMBRANE; CELL SPECIFICITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG POTENCY; DRUG RESPONSE; EFFECTOR CELL; HELPER CELL; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS RECOMBINATION;

3T3 CELLS; ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; GENE PRODUCTS, TAT; IMMUNOTHERAPY; INTERFERON TYPE II; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; ONCOGENE PROTEINS, VIRAL; RECOMBINANT FUSION PROTEINS; SAPONINS; T-LYMPHOCYTES; T-LYMPHOCYTES, HELPER-INDUCER; TUMOR CELLS, CULTURED;

EID: 0042529139     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Hilleman MR: Overview of vaccinology with special reference to papillomavirus vaccines. J Clin Virol 19: 79-90, 2000.
2. Ames BN, Gold LS and Willett WC: The causes and prevention of cancer. Proc Natl Acad Sci USA 92: 5258-5265, 1995.
3. Treanor JJ, Wilkinson BE, Masseoud F, Hu-Primmer J, Battaglia R, O'Brien D, Wolff M, Rabinovich G, Blackwelder W and Katz JM: Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19: 1732-1737, 2001.
4. Barnett SW, Lu S, Srivastava I, Cherpelis S, Gettie A, Blanchard J, Wang S, Mboudjeka I, Leung L, Lian Y, Fong A, Buckner C, Ly A, Hilt S, Ulmer J, Wild CT, Mascola JR and Stamatatos L: The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J Virol 75: 5526-5540, 2001.
5. Goetsch L, Plotnicky-Gilquin H, Aubry JP, De-Lys P, Haeuw JF, Bonnefoy JY, Nguyen NT, Corvaia N and Velin D: BBG2Na an RSV subunit vaccine candidate intramuscularly injected to human confers protection against viral challenge after nasal immunization in mice. Vaccine 19: 4036-4042, 2001.
6. Moingeon P: Cancer vaccines. Vaccine 19: 1305-1326, 2001.
7. Coulie PG: Human tumour antigens recognized by T cells: new perspectives for anti-cancer vaccines? Mol Med Today 3: 261-268, 1997.
8. Geuze HJ: The role of endosomes and lysosomes in MHC class II functioning Immunol Today 19: 282-287, 1998.
9. Schuurhuis DH, Laban S, Toes RE, Ricciardi-Castagnoli P, Kleijmeer MJ, van der Voort EI, Rea D, Offringa R, Geuze HJ, Melief CJ and Ossendorp F: Immature dendritic cells acquire CD8(+) cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or -dependent stimuli. J Exp Med 192: 145-150, 2000.
10. Tao MH and Levy R: Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 362: 755-758, 1993.
11. Chu NR, Wu HB, Wu T, Boux LJ, Siegel MI and Mizzen LA: Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guerin (BCG) hsp65 and HPV16 E7. Clin Exp Immunol 121: 216-225, 2000.
12. Murray K and Shiau AL: The core antigen of hepatitis B virus as a carrier for immunogenic peptides. Biol Chem 380: 277-283, 1999.
13. Greenstone HL, Nieland JD, de Visser KE, De Bruijn ML, Kirnbauer R, Roden RB, Lowy DR, Kast WM and Schiller JT: Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc Natl Acad Sci USA 95: 1800-1805, 1998.
14. Peng S, Frazer IH, Fernando GJ and Zhou J: Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway. Virology 240: 147-157, 1998.
15. Jochmus I, Schafer K, Faath S, Muller M and Gissmann L: Chimeric virus-like particles of the human papillomavirus type 16 (HPV 16) as a prophylactic and therapeutic vaccine. Arch Med Res 30: 269-274, 1999.
16. Vocero-Akbani A, Lissy NA and Dowdy SF: Transduction of full-length Tat fusion proteins directly into mammalian cells: analysis of T cell receptor activation-induced cell death. Methods Enzymol 322: 508-521, 2000.
17. Kim DT, Mitchell DJ, Brockstedt DG, Fong L, Nolan GP, Fathman CG, Engleman EG and Rothbard JB: Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV tat peptide. J Immunol 159: 1666-1668, 1997.
18. Moy P, Daikh Y, Pepinsky B, Thomas D, Fawell S and Barsoum J: Tat-mediated protein delivery can facilitate MHC class I presentation of antigens. Mol Biotechnol 6: 105-113, 1996.
19. Zur Hausen H: Papillomavirus infections - a major cause of human cancers. Biochim Biophys Acta 1288: F55-F78, 1996.
20. Tindle RW: Immunomanipulative strategies for the control of human papillomavirus associated cervical disease. Immunol Res 16: 387-400, 1997.
21. Kast WM, Feltkamp MC, Ressing ME, Vierboom MP, Brandt MP and Melief CJ: Cellular immunity against human papillomavirus associated cervical cancer. Seminars in Virology 7: 117-123, 1996.
22. Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, de Jongh BM, Drijfhout JW, ter Schegget J, Melief CJ and Kast WM: Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16- transformed cells. Eur J Immunol 23: 2242-2249, 1993.
23. Hallez S, Detremmerie O, Giannouli C, Thielemans K, Gajewski TF, Burny A and Leo O: Interleukin-12-secreting human papillomavirus type 16-transformed cells provide a potent cancer vaccine that generates E7-directed immunity. Int J Cancer 81: 428-437, 1999.
24. Arya SK, Guo C, Josephs SF and Wong-Staal F: Trans-activator gene of human T-lymphotropic virus type III (HTLV-III). Science 229: 69-73, 1985.
25. Aida Y and Pabst MJ: Removal of endotoxin from protein solutions by phase separation using Triton X-114. J Immunol Methods 132: 191-195, 1990.
26. Imperiale MJ, Hart RP and Nevins JR: An enhancer-like element in the adenovirus E2 promoter contains sequences essential for uninduced and E1A-induced transcription. Proc Natl Acad Sci USA 82: 381-385, 1985.
27. Desaintes C, Hallez S, Van Alphen P and Burny A: Transcriptional activation of several heterologous promoters by the E6 protein of human papillomavirus type 16. J Virol 66: 325-333, 1992.
28. Muno D, Kominami E and Mizuochi T: Generation of both MHC class I- and class II-restricted antigenic peptides from exogenously added ovalbumin in murine phagosomes. FEBS Lett 478: 178-182, 2000.
29. De Smedt T, Pajak B, Muraille E, Lespagnard L, Heinen E, De Baetselier P, Urbain J, Leo O and Moser M: Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo. J Exp Med 184: 1413-1424, 1996.
30. Aichele P, Brduscha-Riem K, Oehen S, Odermatt B, Zinkernagel RM, Hengartner H and Pircher H: Peptide antigen treatment of naive and virus-immune mice: antigen- specific tolerance versus immunopathology. Immunity 6: 519-529, 1997.
31. Tyagi M, Rusnati M, Presta M and Giacca M: Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans. J Biol Chem 276: 3254-3261, 2001.
32. Barillari G, Sgadari C, Fiorelli V, Samaniego F, Colombini S, Manzari V, Modesti A, Nair BC, Cafaro A, Sturzl M and Ensoli B: The Tat protein of human immunodeficiency virus type-1 promotes vascular cell growth and locomotion by engaging the alpha5betal and alphavbeta3 integrins and by mobilizing sequestered basic fibroblast growth factor. Blood 94: 663-672, 1999.
33. De Bruijn ML, Schuurhuis DH, Vierboom MP, Vermeulen H, de Cock KA, Ooms ME, Ressing ME, Toebes M, Franken KL, Drijfhout JW, Ottenhoff TH, Offringa R and Melief CJ: Immunization with human papillomavirus type 16 (HPV16) oncoprotein- loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells. Cancer Res 58: 724-731, 1998.
34. Schwarze SR, Ho A, Vocero-Akbani A and Dowdy SF: In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285: 1569-1572, 1999.
35. Hung CF, Cheng WF, Chai CY, Hsu KF, He L, Ling M and Wu TC: Improving vaccine potency through intercellular spreading and enhanced MHC class I presentation of antigen. J Immunol 166: 5733-5740, 2001.
36. Michel N, Osen W, Gissmann L, Schumacher TN, Zentgraf H and Muller M: Enhanced immunogenicity of HPV 16 E7 fusion proteins in DNA vaccination. Virology 294: 47-59, 2002.
37. Leifert JA, Lindencrona JA, Charo J and Whitton JL: Enhancing T cell activation and antiviral protection by introducing the HIV-1 protein transduction domain into a DNA vaccine. Hum. Gene Ther 12: 1881-1892, 2001.
38. Fanales-Belasio E, Moretti S, Nappi F, Barillari G, Micheletti F, Cafaro A and Ensoli B: Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses. J. Immunol 168: 197-206, 2002.
39. Wang HY, Fu T, Wang G, Zeng G, Perry-Lalley DM, Yang JC, Restifo NP, Hwu P and Wang RF: Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells. J Clin Invest 109: 1463-1470, 2002.
40. Shibagaki N and Udey MC: Dendritic cells transduced with protein antigens induce cytotoxic lymphocytes and elicit antitumor immunity. J Immunol 168: 2393-2401, 2002.